New Scientific Publication Explains How LDB B-30892 Inhibits The Cytotoxic Effects Of Clostridium Difficile

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: MRSA / Drug Resistance;  GastroIntestinal / Gastroenterology
Article Date: 30 Apr 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

LacPro Industries LLC, a probiotic-based biotherapeutics company, announces today a publication in the peer-reviewed scientific journal, GutPathogens, entitled, " Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells." In this scientific publication, researchers from LacPro, Purdue University, and the Indiana University School of Medicine explain the published in vitro research demonstrating the beneficial effect of its proprietary probiotic strain, LDB B-30892, on Clostridium difficile.

"An early product formulation showed evidence of an ability to provide dietary management of Clostridium difficile infection, thus, it made sense to explore the mechanism of action to explain what we observed in the clinical setting," states author Pratik Banerjee, Ph.D. "This peer-reviewed journal publication supports LacPro's commitment to advance the scientific understandings in the field of probiotics and probiotic-based therapies. As explained in this publication, this technology provides molecular- and cell-biological insights into potential ways to prevent Clostridium difficile infection, a disease affecting 250,000 - 500,000 people each year in the United States."

Clostridium difficile infection (CDI) is a debilitating diarrhea and inflammation of the colon, which is most frequently associated with antibiotic usage and may lead to more serious intestinal conditions, colitis, sepsis, and even death. The incidence of CDI is increasing rapidly and is further complicated by the emergence of a more virulent, drug resistant strain. CDI results in longer hospital stays and additional medical attention, which increases annual U.S. healthcare costs by an estimated $1.1 billion.

The Centers for Disease Control has identified several major clinical problems regarding CDI, including the need for therapeutics that will preventClostridium difficile Infection and also treat severe disease. LacPro is on track to develop a novel therapeutic that can both prevent and treat the disease, without the use of current toxic antibiotic therapies, becoming one of the nation's first probiotic-based biologic therapies. To read the actual publication, please visit http://www.gutpathogens.com/content/1/1/8.

Source
LacPro

• Additional
• References
• Citations